Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML is a federal award for National Cmop Office (36C770) held by Radius Health, Inc. Estimated value $406K ($406K obligated). Current period of performance ends Jun 9, 2022. Last award drew 1 bidder. Place of performance: TUCSON AZ.
Recompete timing
PublicCurrent PoP ended Jun 9, 2022 (1534 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C77022N0121?
36C77022N0121 (Abaloparatide 80mcg 0.04ml PEN 1.56ml) is a National Cmop Office (36C770) award with a potential value of $406K, currently held by Radius Health, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C770-22-N-0121?
36C770-22-N-0121 is the dashed form of PIID 36C77022N0121 (Abaloparatide 80mcg 0.04ml PEN 1.56ml), held by Radius Health, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C77022N0121?
National Cmop Office (36C770) awarded 36C77022N0121 to Radius Health, Inc (potential $406K).
Who is the incumbent on 36C77022N0121?
Radius Health, Inc is the incumbent. The current period of performance ends Jun 9, 2022.
When does Radius Health, Inc’s 36C77022N0121 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 9, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.